OPEN END TURBO OPTIONSSCHEIN SHORT - ASTRAZENECA | Market Closed - Börse Stuttgart 07:12:08 2024-05-28 EDT | ||
| 1.75 EUR | +12.18% |
|
| Current month | -6.42% | ||
| 1 month | -7.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 1.75 | +12.18% |
| 24-05-27 | 1.56 | +0.65% |
| 24-05-24 | 1.55 | +4.03% |
| 24-05-23 | 1.49 | -2.61% |
| 24-05-22 | 1.53 | -7.27% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 07:12 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | Goldman Sachs |
| WKN | GG71EP |
| ISIN | DE000GG71EP0 |
| Date issued | 2024-04-25 |
| Strike | 13,649 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2 € |
|---|---|
| Lowest since issue | 1.49 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
- Stock Market
- Certificates
- Certificat
